{"id":156937,"date":"2022-04-01T02:09:11","date_gmt":"2022-04-01T06:09:11","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/arca-biopharma-reports-topline-results-for-aspen-covid-19-phase-2b-clinical-trial\/"},"modified":"2024-08-18T11:44:10","modified_gmt":"2024-08-18T15:44:10","slug":"arca-biopharma-reports-topline-results-for-aspen-covid-19-phase-2b-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/arca-biopharma-reports-topline-results-for-aspen-covid-19-phase-2b-clinical-trial.php","title":{"rendered":"ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial"},"content":{"rendered":"<p><![CDATA[WESTMINSTER, Colo., March  31, 2022  (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN-COVID-19, a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highly potent and specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D-dimer level from Baseline to Day 8 compared to standard of care heparin.]]><\/p>\n<p>See the original post here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/03\/31\/2414385\/0\/en\/ARCA-biopharma-Reports-Topline-Results-for-ASPEN-COVID-19-Phase-2b-Clinical-Trial.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial\">ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See the original post here: ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/arca-biopharma-reports-topline-results-for-aspen-covid-19-phase-2b-clinical-trial.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-156937","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156937"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=156937"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156937\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=156937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=156937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=156937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}